[{"address1": "320 West 37th Street", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "(917) 580-3099", "website": "https://immunovant.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.", "fullTimeEmployees": 207, "companyOfficers": [{"maxAge": 1, "name": "Dr. Frank M. Torti M.B.A., M.D.", "age": 44, "title": "Executive Chairperson of the Board", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 92500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Salzmann M.B.A., M.D.", "age": 55, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 1348425, "exercisedValue": 0, "unexercisedValue": 54326544}, {"maxAge": 1, "name": "Dr. Jay S. Stout Ph.D.", "age": 60, "title": "Chief Technology Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 683490, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julia G. Butchko Ph.D.", "age": 52, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 747666, "exercisedValue": 0, "unexercisedValue": 18457808}, {"maxAge": 1, "name": "Ms. Eva Renee Barnett M.B.A.", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 871065, "exercisedValue": 0, "unexercisedValue": 706581}, {"maxAge": 1, "name": "Mr. Mark S. Levine", "age": 50, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lauren  Schrier M.B.A.", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Blodgett", "title": "Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William L. Macias M.D., Ph.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 719876, "exercisedValue": 0, "unexercisedValue": 1137932}, {"maxAge": 1, "name": "Mr. Andy  Deig", "title": "Senior Vice President of Strategic Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 30.69, "open": 31.1, "dayLow": 31.05, "dayHigh": 33.69, "regularMarketPreviousClose": 30.69, "regularMarketOpen": 31.1, "regularMarketDayLow": 31.05, "regularMarketDayHigh": 33.69, "beta": 0.713, "forwardPE": -13.081712, "volume": 1968673, "regularMarketVolume": 1968673, "averageVolume": 984774, "averageVolume10days": 693120, "averageDailyVolume10Day": 693120, "bid": 33.58, "ask": 33.67, "bidSize": 100, "askSize": 200, "marketCap": 4920858624, "fiftyTwoWeekLow": 19.5, "fiftyTwoWeekHigh": 45.58, "fiftyDayAverage": 29.2055, "twoHundredDayAverage": 32.71515, "currency": "USD", "enterpriseValue": 3932078592, "floatShares": 65287167, "sharesOutstanding": 146367008, "sharesShort": 12231170, "sharesShortPriorMonth": 10179831, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0836, "heldPercentInsiders": 0.55821997, "heldPercentInstitutions": 0.51612, "shortRatio": 12.93, "shortPercentOfFloat": 0.1911, "bookValue": 3.726, "priceToBook": 9.023081, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -272548992, "trailingEps": -1.91, "forwardEps": -2.57, "pegRatio": -3.42, "enterpriseToEbitda": -13.184, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "IMVT", "underlyingSymbol": "IMVT", "shortName": "Immunovant, Inc.", "longName": "Immunovant, Inc.", "firstTradeDateEpochUtc": 1561123800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d116cec5-659e-37a8-8d49-e874f7dd0477", "gmtOffSetMilliseconds": -14400000, "currentPrice": 33.62, "targetHighPrice": 57.0, "targetLowPrice": 41.0, "targetMeanPrice": 48.62, "targetMedianPrice": 49.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 560004992, "totalCashPerShare": 3.826, "ebitda": -298255008, "totalDebt": 69000, "quickRatio": 12.493, "currentRatio": 13.085, "debtToEquity": 0.013, "returnOnAssets": -0.39658, "returnOnEquity": -0.64545, "freeCashflow": -157402624, "operatingCashflow": -243056000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]